Mutations in the PI3K/Akt/mTOR (mechanistic target of rapamycin kinase)-pathway are amongst the most common across different types of cancer, including not only CRC but also lung, breast, and prostate cancer [19], which have collectively killed more than three million people worldwide in 2020 [1]. This evidence concerns the gene AKT1 and colorectal carcinoma.